AI-09 In Subjects With Glabellar Lines, GL-101
NCT05565950 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72
Last updated 2025-08-27
Summary
AI-09 In Subjects with Glabellar Lines
Conditions
- Glabellar Frown Lines
Interventions
- BIOLOGICAL
-
AI-09
Botulinum toxin, Type A, intramuscular injection, administered once at baseline
- BIOLOGICAL
-
Vehicle
Vehicle Formulation
Sponsors & Collaborators
-
Eirion Therapeutics Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 20 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-09-03
- Primary Completion
- 2024-06-03
- Completion
- 2024-06-03
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Subject Satisfaction With AbobutulinumtoxinA Treatment
NCT03687736 ·Status: COMPLETED ·Phase: PHASE4
-
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
NCT03721016 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
NCT00512135 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)
NCT06585696 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Moderate to Severe Glabellar Lines
NCT04249583 ·Status: COMPLETED ·Phase: PHASE3
-
MT10109L in the Treatment of Glabellar Lines
NCT03795922 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects
NCT03970876 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
NCT04157686 ·Status: COMPLETED ·Phase: PHASE3
-
Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
NCT01391312 ·Status: COMPLETED ·Phase: PHASE4
-
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
NCT02677298 ·Status: COMPLETED ·Phase: PHASE3
-
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
NCT03655691 ·Status: COMPLETED ·Phase: PHASE2
-
The Treatment of Glabellar Frown Lines
NCT02096081 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
NCT05248893 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
NCT02236312 ·Status: COMPLETED ·Phase: PHASE2
-
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
NCT00770211 ·Status: COMPLETED ·Phase: PHASE3
-
Renuvion Dermal System for Dermal Resurfacing
NCT04185909 ·Status: COMPLETED ·Phase: NA
-
Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
NCT04247074 ·Status: COMPLETED ·Phase: PHASE3
-
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
NCT05146999 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT03736928 ·Status: COMPLETED ·Phase: PHASE2
-
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
NCT02353897 ·Status: COMPLETED
-
Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
NCT01776606 ·Status: COMPLETED ·Phase: PHASE3
-
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
NCT03732833 ·Status: COMPLETED ·Phase: PHASE3
-
Post-Market Lower Eyelid Treatment With Renuvion in Greece
NCT05605691 ·Status: COMPLETED ·Phase: NA
-
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
NCT05217355 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness and Safety Study of the Iovera Device for the Temporary Reduction in the Appearance of Forehead Wrinkles
NCT01950065 ·Status: COMPLETED ·Phase: NA